- Home
- PIM vs PRQR Comparison
PIM vs PRQR Comparison
Compare PIM & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PIM | PRQR |
|---|---|---|
| Founded | 1988 | 2012 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 161.7M | 173.8M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | PIM | PRQR |
|---|---|---|
| Price | $3.30 | $1.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $8.14 |
| AVG Volume (30 Days) | 57.5K | ★ 533.5K |
| Earning Date | 01-01-0001 | 03-12-2026 |
| Dividend Yield | ★ 8.28% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | N/A | ★ $18,859,556.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $18.44 |
| P/E Ratio | $63.80 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.90 | $1.07 |
| 52 Week High | $3.28 | $3.10 |
Technical Indicators
Market Signals| Indicator | PIM | PRQR |
|---|---|---|
| Relative Strength Index (RSI) | 44.72 | 38.46 |
| Support Level | $3.29 | $1.58 |
| Resistance Level | $3.34 | $1.80 |
| Average True Range (ATR) | 0.03 | 0.14 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 12.50 | 15.83 |
Price Performance
Historical ComparisonAbout PIM Putnam Master Intermediate Income Trust
Putnam Master Intermediate Income Trust is a closed-end fund. Its investment objective is to provide high current income and relative stability of net asset value. The fund pursues its goal by investing in U.S. high-grade, high-yield, and international fixed-income securities with limited maturities. The fund's portfolio includes the United States Government and agency mortgage obligations; mortgage-backed securities; corporate bonds and notes, and foreign government and agency bonds and notes.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.